SCHEMBL5610946

SCHEMBL5610946

COC(=O)C=Cc1cc(C(=O)O)n[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 10/20 0.54
▸ NPC1 O15118 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ DAO P14920 1/20 0.47
▸ TTR P02766 1/20 0.44
▸ APP P05067 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ TYR P14679 1/20 0.44
▸ CA7 P43166 1/20 0.44
▸ CA9 Q16790 1/20 0.44
▸ CA14 Q9ULX7 1/20 0.44
▸ HCAR3 P49019 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5610945 1.00 HCAR2 (0.54) HCAR2NPC1POLBRAB9AMEN1
SCHEMBL5599559 0.81 HCAR2 (0.63) HCAR2NPC1POLBRAB9ADAO
SCHEMBL14586657 0.81 HCAR2 (0.63) HCAR2NPC1POLBRAB9ADAO
SCHEMBL5599558 0.81 HCAR2 (0.63) HCAR2NPC1POLBRAB9ADAO
SCHEMBL5599431 0.80 HCAR2 (0.58) HCAR2NPC1POLBRAB9ADAO
SCHEMBL5599435 0.80 HCAR2 (0.58) HCAR2NPC1POLBRAB9ADAO
SCHEMBL14586656 0.74 HCAR2 (0.63) HCAR2NPC1POLBRAB9AMEN1
SCHEMBL5599209 0.74 HCAR2 (0.63) HCAR2NPC1POLBRAB9AMEN1
SCHEMBL5599204 0.74 HCAR2 (0.63) HCAR2NPC1POLBRAB9AMEN1
SCHEMBL15728491 0.74 KMT2A (0.47) NPC1POLBRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ARENA PHARMACEUTICALS, INC. (US) 2007-02-08 — — US claimed
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ARENA PHARMACEUTICALS, INC. (US) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032537-A1 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases ACE, AGTR2, ACE2 HCAR2 52/4885NPC1 916/4885POLB 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback